Improved uroselectivity might be achieved through alterations in structure or route of administration.[34] New drug classes under investigation for OAB include ??3-adrenoceptor agonists, purinergic receptor antagonists, phosphodiesterase inhibitors, neurokinin-1 receptor antagonists, opioids, and Rho-kinase inhibitors.[34] However, clinical data, particularly comparing efficacy and safety is await